Citations

Clear

1011 citation(s) found for "Barry, WT".

Free, Complexed and Total Serum Prostate Specific Antigen: The Establishment of Appropriate Reference Ranges for their Concentrations and Ratios
Oesterling, Joseph E., Jacobsen, Steven J. , Klee, George G., Petterson, Kim, Piironen, Timo, Abrahamsson, Per-Anders, Dowell, Barry L., Lövgren, Timo, Stenman, Ulf‐Håkan , Lilja, Hans

Mayo Clinic

Journal of Urology | January 17, 2006 | Volume: 154 | Issue: 3 | Pages: 1090-1095

10.1016/s0022-5347(01)66984-2 | PMID 7543605 Get It

The NHLBI Lymphangioleiomyomatosis Registry
Ryu, Jay H. , Moss, Joel , Beck, Gerald J. , Lee, Jar-Chi, Brown, Kevin K. , Chapman, Jeffrey T., Finlay, Geraldine A., Olson, Eric J. , Ruoss, Stephen J. , Maurer, J.R., Raffin, Thomas A., Peavy, Hannah, Taveira‐DaSilva, Angelo M., McCormack, Francis X. , Avila, Nilo A., DeCastro, Rosamma, Jacobs, Susan S. , Stylianou, Mario, Fanburg, Barry L., Lee, Jar-Chi, McCarthy, Kevin , McCormack, Francis X , Ryu, Jay H

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | October 6, 2005 | Volume: 173 | Issue: 1 | Pages: 105-111

10.1164/rccm.200409-1298oc | PMID 16210669 Get It

Abstract Rationale Pulmonary lymphangioleiomyomatosis is a progressive cystic lung disease that is associated with infiltration of atypical smooth muscle–like cells. Previous descriptions of clinical characteristics of subjects with lymphangioleiomyomatosis have been based on a limited number of patients. Objectives To describe the clinical characteristics of subjects with pulmonary lymphangioleiomyomatosis, both sporadic and tuberous sclerosis–related forms. Methods Over a 3-yr period, from 1998 to 2001, 243 subjects with pulmonary lymphangioleiomyomatosis were enrolled into a national registry; 13 subjects who had already undergone lung transplantation were excluded for the purposes of this report. Measurements and Main Results All 230 subjects were women, aged 18 to 76 yr (mean ± SE, 44.5 ± 0.65 yr). The average age at onset of symptoms was 38.9 ± 0.73 yr and at diagnosis was 41.0 ± 0.65 yr. Tuberous sclerosis complex was present in 14.8% of subjects. Pulmonary manifestations, most commonly spontaneous pneumothorax, were the primary events leading to the diagnosis in 86.5% of cases. Nearly 55% of the subjects were being treated with a progesterone derivative. An obstructive pattern on pulmonary function testing was observed in 57.3% of the subjects, whereas 33.9% had normal spirometric results. Women with tuberous sclerosis–related lymphangioleiomyomatosis were younger and had less impaired lung function compared with those with the sporadic form. Conclusions The age range of women afflicted with pulmonary lymphangioleiomyomatosis is broader than previously appreciated and the degree of pulmonary function can be quite variable, with one-third of subjects having normal spirometry at enrollment into this registry.
Age- and Gender-Related Ventricular-Vascular Stiffening
Redfield, Margaret M. , Jacobsen, Steven J. , Rodeheffer, Richard J. , Borlaug, Barry A. , Kass, David A.

Mayo Clinic

Circulation | October 3, 2005 | Volume: 112 | Issue: 15 | Pages: 2254-2262

10.1161/circulationaha.105.541078 | PMID 16203909 Get It

Background— Increases in vascular (Ea), ventricular systolic (Ees), and ventricular diastolic (Ed) elastance (stiffness) may contribute to the pathogenesis of heart failure (HF) with preserved ejection fraction (HFnlEF). The prevalence of HFnlEF increases strikingly with age, particularly in women. We hypothesized that ventricular-vascular stiffening may occur with age and be more pronounced in women in the general community. Methods and Results— In a cross-sectional sample of Olmsted County, Minn, residents ≥45 years old (n=2042), clinical data, Doppler echocardiography, and blood pressure (BP) measurements were obtained. Ea was calculated from stroke volume and systolic BP and indexed to body size (EaI). Ees was calculated by a modified single-beat method using systolic and diastolic BP, stroke volume, ejection fraction, timing intervals, and an estimated normalized ventricular elastance at arterial end diastole. Operant Ed was calculated from Doppler indices reflective of atrial pressures and the diastolic filling volume. EaI, Ees, and Ed all increased with age in men and in women ( P <0.0001 for all). Ees increased more steeply with age in women ( P =0.002). Adjusted for age, EaI, Ees, and Ed were higher in women than in men ( P <0.0001 for all). Findings were similar in those without known or suspected cardiovascular disease (n=623). Conclusions— In the community, advancing age and female gender are associated with increases in vascular and ventricular systolic and diastolic stiffness even in the absence of cardiovascular disease. We speculate that this combined ventricular-vascular stiffening may contribute to the increased prevalence of HFnlEF in elderly persons and particularly in elderly women.
Malignant pheochromocytoma: current status and initiatives for future progress
Eisenhofer, Graeme , Bornstein, Stefan R. , Brouwers, Frederieke M., Cheung, Nai‐Kong V. , Giordano, Thomas J. , Lehnert, Hendrik, Manger, William M., Neumann, Hartmut P.H., Pacák, Karel , Shulkin, Barry L. , Smith, David I, Tischler, Arthur S. , Dahia, Patricia L. M. , Krijger, Ronald R. de , Greene, Lloyd A. , Goldstein, David S. , Maris, John M. , Smith, David I, Young, William F. , Shulkin, Barry L

Mayo Clinic

Endocrine-Related Cancer | December 2, 2004 | Volume: 11 | Issue: 3 | Pages: 423-436

10.1677/erc.1.00829 | PMID 15369446 Get It

Abstract Pheochromocytomas are rare catecholamine-producing neuroendocrine tumors that are usually benign, but which may also present as or develop into a malignancy. Predicting such behavior is notoriously difficult and there are currently no curative treatments for malignant tumors. This report follows from a workshop at the Banbury Conference Center, Cold Spring Harbor, New York, on the 16th–18th November 2003, held to review the state of science and to facilitate future progress in the diagnosis and treatment of malignant pheochromocytoma. The rarity of the tumor and the resulting fragmented nature of studies, typically involving small numbers of patients, represent limiting factors to the development of effective treatments and diagnostic or prognostic markers for malignant disease. Such development is being facilitated by the availability of new genomics-based tools, but for such approaches to succeed ultimately requires comprehensive clinical studies involving large numbers of patients, stringently collected clinical data and tumor samples, and interdisciplinary collaborations among multiple specialist centers. Nevertheless, the well-characterized hereditary basis and the unique functional nature of these neuroendocrine tumors provide a useful framework that offers advantages for establishing the pathways of tumorigenesis and malignancy. Such findings may have relevance for understanding the basis of other more common malignancies where similar frameworks are not available. As the relevant pathways leading to pheochromocytoma are established it should be possible to take advantage of the new generation of drugs being developed to target specific pathways in other malignancies. Again the success of this will require well-designed and coordinated multicenter studies.
Prevention of Sudden Death in Hypertrophic Cardiomyopathy
Maron, Barry J. , Shen, Win-Kuang, Spirito, Paolo , Boriani, Giuseppe

Mayo Clinic

Circulation | October 11, 2004 | Volume: 110 | Issue: 15 | Pages: No page available

10.1161/01.cir.0000144463.65977.c9 | PMID 15477422 Get It

Management issues in dyspepsia: current consensus and controversies
Vakil, Nimish , Delaney, Brendan , Marshall, Barry J. , Bytzer, Peter , Boer, Wink de, Jones, Roger , Agréus, Lars , Talley, Nicholas J. , Engstrand, Lars , Malfertheiner, Peter

Mayo Clinic

Scandinavian Journal of Gastroenterology | September 29, 2004 | Volume: 39 | Issue: 10 | Pages: 913-918

10.1080/00365520410003452 | PMID 15513327 Get It

Idiopathic Interstitial Pneumonia
Flaherty, Kevin R. , King, Talmadge E. , Raghu, Ganesh , Lynch, Joseph P., Colby, Thomas V. , Gross, Barry H., Kazerooni, Ella A. , Toews, Galen B., Long, Qi , Murray, Susan , Lama, Vibha N. , Gay, Steven E., Long, Qi , Travis, William D. , Martínez, Fernando J. , Long, Qi

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 15, 2004 | Volume: 170 | Issue: 8 | Pages: 904-910

10.1164/rccm.200402-147oc | PMID 15256390 Get It

Abstract Current guidelines recommend that the clinician, radiologist, and pathologist work together to establish a diagnosis of idiopathic interstitial pneumonia. Three clinicians, two radiologists, and two pathologists reviewed 58 consecutive cases of suspected idiopathic interstitial pneumonia. Each participant was provided information in a sequential manner and was asked to record their diagnostic impression and level of confidence at each step. Interobserver agreement improved from the beginning to the end of the review. After the presentation of histopathologic information, radiologists changed their diagnostic impression more often than did clinicians. In general, as more information was provided the confidence level for a given diagnosis improved, and the diagnoses rendered with a high level of confidence were more likely congruent with the final pathologic consensus diagnosis. The final consensus pathologist diagnosis was idiopathic pulmonary fibrosis in 30 cases. Clinicians identified 75% and radiologists identified 48% of these cases before presentation of the histopathologic information. Histopathologic information has the greatest impact on the final diagnosis, especially when the initial clinical/radiographic diagnosis is not idiopathic pulmonary fibrosis. We conclude that dynamic interactions between clinicians, radiologists, and pathologists improve interobserver agreement and diagnostic confidence.
Multi-Institutional Trial of Preoperative Chemoradiotherapy in Patients With Potentially Resectable Gastric Carcinoma
Mansfield, Paul F. , Janjan, Nora A., Morris, Jeffrey S. , Pisters, Peter W. T., Lynch, Patrick M. , Feig, Barry W. , Myerson, Robert J., Nivers, R., Cohen, Deborah S., Gunderson, Leonard L., Ajani, Jaffer A.

Mayo Clinic

Journal of Clinical Oncology | July 14, 2004 | Volume: 22 | Issue: 14 | Pages: 2774-2780

10.1200/jco.2004.01.015 | PMID 15254045 Get It

Purpose In the West, curative (R0) resection is achieved in approximately 50% of patients with localized gastric carcinoma, and more than 60% die of cancer following an R0 resection. A multi-institutional study of preoperative chemoradiotherapy was done to assess the R0 resection rate, pathologic complete response (pathCR) rate, safety, and survival in patients with resectable gastric carcinoma. Patients and Methods Operable patients with localized gastric adenocarcinoma were eligible. Staging also included a laparoscopy and endoscopic ultrasonography (EUS). Patients received up to two 28-day cycles of induction chemotherapy of fluorouracil, leucovorin, and cisplatin, followed by 45 Gy of radiation plus concurrent fluorouracil. Patients were then staged and surgery was attempted. Results Thirty-four patients were registered at three institutions. One ineligible patient was excluded. Most patients had a promixal cancer and EUST3N1 designation. Twenty-eight (85%) of 33 patients underwent surgery. The R0 resection rate was 70% and pathCR rate was 30%. A pathologic partial response (< 10% residual carcinoma in the primary) occurred in eight patients (24%). EUS T plus N and postsurgery T plus N correlation showed significant downstaging (P = < .01). The median survival time for 33 patients was 33.7 months. Patients achieving a pathCR or pathPR had a significantly longer median survival time (63.9 months) than those achieving less than pathPR (12.6 months; P = .03). There were two treatment-related deaths. Conclusion Our data suggest that the three-step strategy of preoperative induction chemotherapy followed by chemoradiotherapy resulted in substantial pathologic response that resulted in durable survival time. This strategy is worthy of a direct comparison with postoperative adjuvant chemoradiotherapy.
Enhanced Monocyte Chemoattractant Protein-3/CC Chemokine Ligand-7 in Usual Interstitial Pneumonia
Choi, Esther , Carpenter, Kristin J., Kunkel, Steven L. , Evanoff, Holly, Flaherty, Kevin R. , Toews, Galen B., Colby, Thomas V. , Kazerooni, Ella A. , Gross, Barry H., Hogaboam, Cory M. , Jakubzick, Claudia , Martínez, Fernando J. , Travis, William D.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 15, 2004 | Volume: 170 | Issue: 5 | Pages: 508-515

10.1164/rccm.200401-002oc | PMID 15191918 Get It

Abstract Chemokines are increased and may exert effects on both inflammatory and remodeling events in idiopathic pulmonary pneumonia (IIP). Accordingly, we examined the concomitant expression of inflammatory CC chemotactic cytokines or chemokines and their corresponding receptors in surgical lung biopsies obtained at the time of disease diagnosis and pulmonary fibroblasts grown from these biopsies. By gene array analysis, upper and lower lobe biopsies and primary fibroblast lines from patients with usual interstitial pneumonia (UIP), nonspecific interstitial pneumonia, and respiratory bronchiolitis-interstitial lung disease, but not patients without IIP, exhibited CCL7 gene expression. TAQMAN, immunohistochemical, and ELISA analyses confirmed that CCL7 was expressed at significantly higher levels in UIP lung biopsies compared with biopsies from patients with nonspecific interstitial pneumonia, respiratory bronchiolitis-interstitial lung disease, and from patients without IIP. Higher levels of CCL7 were present in cultures of IIP fibroblasts compared with non-IIP fibroblasts, and CCL5, a CCR5 agonist, significantly increased the synthesis of CCL7 by UIP fibroblasts. Together, these data suggest that CCL7 is highly expressed in biopsies and pulmonary fibroblast lines obtained from patients with UIP relative to patients with other IIP and patients without IIP, and that this CC chemokine may have a major role in the progression of fibrosis in this IIP patient group.
Outcomes in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention in the Current Era
Mathew, Verghese, Williams, Brent A. , Laskey, Warren K., Willerson, James T., Tilbury, R. Thomas, Davis, Barry R. , Holmes, David R. , Gersh, Bernard J.

Mayo Clinic

Circulation | January 19, 2004 | Volume: 109 | Issue: 4 | Pages: 476-480

10.1161/01.cir.0000109693.64957.20 | PMID 14732749 Get It

Background— Diabetes portends an adverse prognosis in patients undergoing percutaneous coronary intervention (PCI). Whether improvements in current clinical practice (stents, IIb/IIIa antagonists) have resulted in substantial improvement of these outcomes remains an issue. The aim of this study was to determine the influence of diabetes on 9-month outcomes of patients undergoing PCI in the current era. Methods and Results— The 11 482 patients enrolled in the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial were stratified according to the presence (n=2694) or absence (n=8798) of diabetes. Diabetic patients were older; were more likely to be female; had a higher proportion of congestive failure, hypertension, prior CABG, and unstable angina; and had higher body mass index and lower ejection fraction than nondiabetic patients ( P <0.01 for all comparisons). The degree of multivessel disease was similar between the two groups. American College of Cardiology/American Heart Association type C lesions were more common in diabetic patients (17% versus 15%, P <0.01). Angiographic and procedural success rates and in-hospital events were similar between the two groups. The primary end point of death, myocardial infarction, or target vessel revascularization (TVR) was analyzed as time-to-first event within 9 months of the index PCI. After adjusting for certain baseline characteristics, diabetes was independently associated with death at 9 months (relative risk [RR], 1.87; 95% CI, 1.31 to 2.68, P <0.01) and with an increased likelihood of TVR (RR, 1.27; 95% CI, 1.14 to 1.42, P <0.01), as well as the composite end point of death/myocardial infarction/TVR (RR, 1.26; 95% CI, 1.13 to 1.40, P <0.01). Conclusions— Despite advances in interventional techniques, diabetes remains a significant independent predictor of adverse events in the intermediate term after PCI.